No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relaxant, antitussive, antipruritic, scabicide, anti-inflammatory, antipyretic, analgesic, muscle relaxant, anxiolytic, antiemetic, anticonvulsant, anti-ulcerative, antihypertensive, a-blocker, vasodilator, bronchodilator, anxiolytic, tranquilizer, local anesthetic, decongestant, antispasmodic, neuroprotective, antimigraine, pharmaceutic aid/lubricant, antiglaucoma agent, hyponatremia, antidepressant, sedative, and analgesic, as well as treatment for hyperparathyroidism and urinary frequency, benign prostatic hypertrophy, and Herpes virus helicase-primase inhibitor. SYN-TECH Chem. & Pharm. Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
www.syn-tech.com.twNo one on the platform currently holds 1777.TWO.
No tracked institution reports a position in 1777.TWO as of their last filing.
No one on the platform has traded 1777.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.2% | 12.0% | 13.1% | — | — | — |
| Rev. Growth % | 3.4% | 5.7% | ||||
| Profit Margin % | 20.1% | 24.7% | 20.8% | |||
| Free Cash Flow Margin % | 38.5% | 10.7% | 9.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $930M | -15.2% | $5.49 | $5.49–$5.49 | — | 1 |
| 2027 | $1.0B | +7.5% | $6.06 | $6.06–$6.06 | — | 1 |
| 2028 | $744M | -25.6% | $2.85 | $2.85–$2.85 | — | 1 |
| 2029 | $951M | +27.8% | $6.95 | $6.95–$6.95 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $1.54 | $2.03 | +31.8% |
| 2026-05-07 | $1.54 | $1.61 | +4.5% |
| 2026-02-23 | $1.45 | $2.06 | +42.1% |
| 2024-08-12 | $0.59 | $2.21 | +274.6% |
| $29.10 |
| +2.46% |
| $2.0B |
| — |
| 6610.TWOTWi Biotechnology, Inc. | $40.05 | +5.95% | $8.2B | — |
| 6634.TWOSinew Pharma Inc. | $59.00 | +5.55% | $4.2B | — |
Source: Financial Modeling Prep · peers by sector/industry